Pharmacokinetic study and bioavailability of three marketed compounds releasing p-chlorophenoxyisobutyric acid (CPIB) in volunteers.
The bioavailability and the pharmacokinetics of three hypolipidemic marketed drugs: clofibride, clofibrate and basic aluminium salt of p-chlorophenoxyisobutyric acid (CPIB), releasing in vivo p-chlorophenoxyisobutyric acid (CPIB), the active metabolite, have been investigated in seven healthy male volunteers. The plasma and urinary concentrations of CPIB were determined by a gaschromatographic method, after oral ingestion of a single dose of each compound, releasing 1,3 g of CPIB, as a therapeutic dose, according to a crossover repetition design. The CPIB peak plasma level achieved by clofibride occurs earlier and is higher than this observed after clofibrate, but the CPIB bioavailability, measured by the areas under the plasma concentration-time curve released by clofibride and clofibrate, has be found similar. On the other hand, the CPIB released by the basic aluminium salt of CPIB is slowly absorbed as shown by the very low plasma levels and CPIB urinary excretion during this 24h study.
D000328:Adult; D000924:Anticholesteremic Agents / Q000378:metabolism*; D001682:Biological Availability; D002087:Butyrates / Q000378:metabolism*; D002849:Chromatography, Gas / Q000379:methods; D002994:Clofibrate / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008297:Male
D000924:Anticholesteremic Agents; D002087:Butyrates; D002994:Clofibrate